Physician Info

Consensus Panel 1 (CP1) of the 11th International Workshop on Waldenstrom's Macroglobulinemia (IWWM-11) was tasked with updating guidelines for the management of symptomatic, treatment-naïve patients with WM.  Their report is available here.

Two clinical trials are available for WM patients at various sites across Canada: https://clinicaltrials.gov/ct2/show/NCT04624906: Treatment naive patients; Bendamustine + Rituximab, plus one year of Acalabrutinib https://clinicaltrials.gov/ct2/show/NCT04728893: R/R patients; Nemtabrutinib (a non-covalent BTK inhibitor)

A summary of the 11th International Workshop on WM (iwWM) held October, 2022, has been published at https://link.springer.com/article/10.1007/s12254-023-00876-3.  Click on the "Download PDF" box on the right.

Partially funded by the WMFC and presented at ASH in December, 2022, this research identified three subtypes of WM. The full abstract that Dr. Hunter presented at ASH is available here. Two other WM-related abstracts using the multiomic analysis from Dr. Hunter’s research were also presented at ASH: An in-depth investigation into why epigenomic regulation is so important to MYD88 mutations is available here The data also has been applied to investigating why ibrutinib (and by extension other BTK inhibitors) may result in long Progression-Free Survival (PFS); that abstract is available here

Dr. Steve Treon of the Dana-Farber Cancer Institute presents a thorough summary of the latest knowledge of WM and its current and upcoming treatments.  See https://youtu.be/JCrdW4VpNpw.

This journal article by a set of researchers from across Canada provides an overview of treatment options for WM, and their usage in current (2022) Canadian WM treatment.  See https://www.mdpi.com/1718-7729/29/10/560.